PSME1
Proteasome activator complex subunit 1
Also known as: IFI5111, PA28alpha, PSME1_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q06323
- Gene
- PSME1
- Ensembl
- ENSG00000092010
- Chromosome
- 14
- Canonical length
- 249 aa
- Protein class
- Plasma proteins, Predicted intracellular proteins
- Subcellular location
- Nuclear bodies,Cytosol
- Quaternary structure
- Homoheptamer
OverviewNCBI Gene
The 26S proteasome is a multicatalytic proteinase complex with a highly ordered structure composed of 2 complexes, a 20S core and a 19S regulator. The 20S core is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. The 19S regulator is composed of a base, which contains 6 ATPase subunits and 2 non-ATPase subunits, and a lid, which contains up to 10 non-ATPase subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. The immunoproteasome contains an alternate regulator, referred to as the 11S regulator or PA28, that replaces the 19S regulator. Three subunits (alpha, beta and gamma) of the 11S regulator have been identified. This gene encodes the alpha subunit of the 11S regulator, one of the two 11S subunits that is induced by gamma-interferon. Three alpha and three beta subunits combine to form a heterohexameric ring. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Jul 2013]
Canonical amino-acid sequenceUniProt
249 residues, UniProt reviewed canonical sequence.
>Q06323|PSME1
1 MAMLRVQPEA QAKVDVFRED LCTKTENLLG SYFPKKISEL DAFLKEPALN EANLSNLKAP
61 LDIPVPDPVK EKEKEERKKQ QEKEDKDEKK KGEDEDKGPP CGPVNCNEKI VVLLQRLKPE
121 IKDVIEQLNL VTTWLQLQIP RIEDGNNFGV AVQEKVFELM TSLHTKLEGF HTQISKYFSE
181 RGDAVTKAAK QPHVGDYRQL VHELDEAEYR DIRLMVMEIR NAYAVLYDII LKNFEKLKKP
241 RGETKGMIYLocalizationUniProt · AlphaFold · HPA
Whether an antibody against PSME1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.36
- Highest tissue expression
- 273 nTPM
Expression across tissuesHPA
Tissue
- spleen: 273 nTPM
- kidney: 246 nTPM
- adrenal gland: 232 nTPM
- liver: 220 nTPM
- small intestine: 211 nTPM
- lung: 187 nTPM
Single-cell type
- enterocytes: 541 nCPM
- gastric progenitor cells: 422 nCPM
- decidual stromal cells: 403 nCPM
- migrating cytotrophoblasts: 353 nCPM
- cytotrophoblasts: 326 nCPM
- enteric transient amplifying cells: 310 nCPM
Immune cell
- total PBMC: 979 nTPM
- neutrophil: 657 nTPM
- non-classical monocyte: 578 nTPM
- intermediate monocyte: 571 nTPM
- eosinophil: 554 nTPM
- T-reg: 540 nTPM
Brain region
- medulla oblongata: 26 nTPM
- white matter: 26 nTPM
- spinal cord: 24 nTPM
- hypothalamus: 23 nTPM
- thalamus: 22 nTPM
- pons: 21 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about PSME1.
Disease | ImmuneIEDB
Conditions an epitope on PSME1 was assayed in.
- type 1 diabetes mellitus T cell
ReferencesPubMed · IEDB
Publications for PSME1 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
2 publications
- Autoimmune response to proteasome activator 28alpha in patients with connective tissue diseases.
2004 · J Rheumatol · RCR 0.3 · 15 citations - Anti-proteasome activator 28alpha is a novel anti-cytoplasmic antibody in patients with systemic lupus erythematosus and Sjögren's syndrome.
2009 · Mod Rheumatol · RCR 0.1 · 5 citations
Reference: T cellIEDB
1 publication
- The antigen presentation landscape of cytokine-stressed human pancreatic islets.
2025 · Cell Rep · RCR 2.5 · 8 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. IEDB — curated epitope assays from the Immune Epitope Database (Vita et al., Nucleic Acids Research 2019). Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.65
- gnomAD pLI
- 0.13
- gnomAD missense Z
- 0.52
- DepMap mean gene effect
- -0.11
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 5% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- antigen processing and presentation of exogenous antigen
- regulation of G1/S transition of mitotic cell cycle
- regulation of proteasomal protein catabolic process
Molecular functions
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Proteasome activator PA28, N-terminal domain
- Proteasome activator PA28, C-terminal domain
- Proteasome activator PA28
- Proteasome activator superfamily
- Proteasome activator PA28, N-terminal domain superfamily
- Proteasome activator PA28, C-terminal domain superfamily
- Proteasome activator PA28, N-terminal
- Proteasome activator PA28, C-terminal
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of PSME1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads PSME1 as an antibody target. Whether an autoantibody or antibody against PSME1 could matter depends on whether native PSME1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
PSME1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label PSME1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...